Hypera SA (DE:HM6A)
FRANKFURT:HM6A
HM6A Stock Chart & Stats
€3.72
-€0.08(-2.73%)
At close: 4:00 PM EST
€3.72
-€0.08(-2.73%)
Day’s Range― - ―
52-Week Range€3.14 - €4.36
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€2.48B
Enterprise Value€21.83B
Total Cash (Recent Filing)€2.28B
Total Debt (Recent Filing)€8.62B
Price to Earnings (P/E)7.9
Beta0.17
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.66
Shares Outstanding633,420,840
10 Day Avg. Volume0
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.86
P/FCF Ratio8.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Strong MarginsConsistent top-line growth with durable gross and operating margins indicates the company maintains pricing power and product mix advantages in Brazil. These margin levels support long-term profitability and reinvestment capacity across R&D, marketing, and manufacturing to sustain competitive positioning.
Improving Leverage And Balance-sheet De-riskingDeclining leverage and a rising equity base reduce refinancing and liquidity risk, improving financial flexibility. This structural improvement supports investment in growth initiatives, M&A optionality, and resilience through industry cycles, enhancing the firm's long-term stability.
Positive Free Cash Flow GenerationSustained positive operating and free cash flow signals the business generates internal funding for dividends, capex, and debt reduction. Even with slower conversion, consistent FCF demonstrates durable cash generation from core branded pharma and consumer health sales, underpinning long-term capital allocation.
Bears Say
Weaker Cash Conversion And Declining FCF GrowthDeclining free cash flow growth and deteriorating cash conversion point to rising working-capital needs or cost pressures. Persisting weakness here can constrain reinvestment, dividends, and deleveraging ability, making earnings less valuable unless operational efficiency improves.
Margins Below Recent Peak LevelsA reversion from peak margins suggests less favorable product mix, pricing pressure, or higher costs. If sustained, lower margin envelope reduces margin of safety on earnings, limits free cash flow upside, and could weaken competitive advantage versus peers with steadier margin profiles.
Cooling Return On EquityA meaningful decline in ROE signals reduced capital efficiency and weaker returns to shareholders. Persistently lower ROE may reflect slower growth, margin compression, or suboptimal capital allocation, all of which can limit long-term shareholder value creation absent strategic remediation.
Hypera SA News
HM6A FAQ
What was Hypera SA’s price range in the past 12 months?
Hypera SA lowest stock price was €3.14 and its highest was €4.36 in the past 12 months.
What is Hypera SA’s market cap?
Hypera SA’s market cap is €2.48B.
When is Hypera SA’s upcoming earnings report date?
Hypera SA’s upcoming earnings report date is Aug 06, 2026 which is in 59 days.
How were Hypera SA’s earnings last quarter?
Hypera SA released its earnings results on Apr 28, 2026. The company reported €0.089 earnings per share for the quarter, beating the consensus estimate of N/A by €0.089.
Is Hypera SA overvalued?
According to Wall Street analysts Hypera SA’s price is currently Overvalued.
Does Hypera SA pay dividends?
Hypera SA does not currently pay dividends.
What is Hypera SA’s EPS estimate?
Hypera SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hypera SA have?
Hypera SA has 633,420,840 shares outstanding.
What happened to Hypera SA’s price movement after its last earnings report?
Hypera SA reported an EPS of €0.089 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.083%.
Which hedge fund is a major shareholder of Hypera SA?
Currently, no hedge funds are holding shares in DE:HM6A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hypera SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.43%
12-Months-Change
Fundamentals
Return on Equity
13.23%
Trailing 12-Months
Asset Growth
17.40%
Trailing 12-Months
Company Description
Hypera SA
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
HM6A Company Deck
HM6A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including strong revenue growth, successful working capital optimization, and record operational cash flow. However, challenges were noted in the institutional market and R&D approval delays. Despite these challenges, the overall performance and strategic initiatives indicate a positive outlook.View all DE:HM6A earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Options Prices
Currently, No data available
---